Metformin Inhibits the Urea Cycle and Reduces Putrescine Generation in Colorectal Cancer Cell Lines. 2021

Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
Department of Anatomy, College of Basic Medicine, Chongqing Medical University, Chongqing 400016, China.

The urea cycle (UC) removes the excess nitrogen and ammonia generated by nitrogen-containing compound composites or protein breakdown in the human body. Research has shown that changes in UC enzymes are not only related to tumorigenesis and tumor development but also associated with poor survival in hepatocellular, breast, and colorectal cancers (CRC), etc. Cytoplasmic ornithine, the intermediate product of the urea cycle, is a specific substrate for ornithine decarboxylase (ODC, also known as ODC1) for the production of putrescine and is required for tumor growth. Polyamines (spermidine, spermine, and their precursor putrescine) play central roles in more than half of the steps of colorectal tumorigenesis. Given the close connection between polyamines and cancer, the regulation of polyamine metabolic pathways has attracted attention regarding the mechanisms of action of chemical drugs used to prevent CRC, as the drug most widely used for treating type 2 diabetes (T2D), metformin (Met) exhibits antitumor activity against a variety of cancer cells, with a vaguely defined mechanism. In addition, the influence of metformin on the UC and putrescine generation in colorectal cancer has remained unclear. In our study, we investigated the effect of metformin on the UC and putrescine generation of CRC in vivo and in vitro and elucidated the underlying mechanisms. In nude mice bearing HCT116 tumor xenografts, the administration of metformin inhibited tumor growth without affecting body weight. In addition, metformin treatment increased the expression of monophosphate (AMP)-activated protein kinase (AMPK) and p53 in both HCT116 xenografts and colorectal cancer cell lines and decreased the expression of the urea cycle enzymes, including carbamoyl phosphate synthase 1 (CPS1), arginase 1 (ARG1), ornithine trans-carbamylase (OTC), and ODC. The putrescine levels in both HCT116 xenografts and HCT116 cells decreased after metformin treatment. These results demonstrate that metformin inhibited CRC cell proliferation via activating AMPK/p53 and that there was an association between metformin, urea cycle inhibition and a reduction in putrescine generation.

UI MeSH Term Description Entries
D008687 Metformin A biguanide hypoglycemic agent used in the treatment of non-insulin-dependent diabetes mellitus not responding to dietary modification. Metformin improves glycemic control by improving insulin sensitivity and decreasing intestinal absorption of glucose. (From Martindale, The Extra Pharmacopoeia, 30th ed, p289) Dimethylguanylguanidine,Dimethylbiguanidine,Glucophage,Metformin HCl,Metformin Hydrochloride,HCl, Metformin,Hydrochloride, Metformin
D011700 Putrescine A toxic diamine formed by putrefaction from the decarboxylation of arginine and ornithine. 1,4-Butanediamine,1,4-Diaminobutane,Tetramethylenediamine,1,4 Butanediamine,1,4 Diaminobutane
D004195 Disease Models, Animal Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases. Animal Disease Model,Animal Disease Models,Disease Model, Animal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014508 Urea A compound formed in the liver from ammonia produced by the deamination of amino acids. It is the principal end product of protein catabolism and constitutes about one half of the total urinary solids. Basodexan,Carbamide,Carmol
D015179 Colorectal Neoplasms Tumors or cancer of the COLON or the RECTUM or both. Risk factors for colorectal cancer include chronic ULCERATIVE COLITIS; FAMILIAL POLYPOSIS COLI; exposure to ASBESTOS; and irradiation of the CERVIX UTERI. Colorectal Cancer,Colorectal Carcinoma,Colorectal Tumors,Neoplasms, Colorectal,Cancer, Colorectal,Cancers, Colorectal,Carcinoma, Colorectal,Carcinomas, Colorectal,Colorectal Cancers,Colorectal Carcinomas,Colorectal Neoplasm,Colorectal Tumor,Neoplasm, Colorectal,Tumor, Colorectal,Tumors, Colorectal
D015415 Biomarkers Measurable and quantifiable biological parameters (e.g., specific enzyme concentration, specific hormone concentration, specific gene phenotype distribution in a population, presence of biological substances) which serve as indices for health- and physiology-related assessments, such as disease risk, psychiatric disorders, ENVIRONMENTAL EXPOSURE and its effects, disease diagnosis; METABOLIC PROCESSES; SUBSTANCE ABUSE; PREGNANCY; cell line development; EPIDEMIOLOGIC STUDIES; etc. Biochemical Markers,Biological Markers,Biomarker,Clinical Markers,Immunologic Markers,Laboratory Markers,Markers, Biochemical,Markers, Biological,Markers, Clinical,Markers, Immunologic,Markers, Laboratory,Markers, Serum,Markers, Surrogate,Markers, Viral,Serum Markers,Surrogate Markers,Viral Markers,Biochemical Marker,Biologic Marker,Biologic Markers,Clinical Marker,Immune Marker,Immune Markers,Immunologic Marker,Laboratory Marker,Marker, Biochemical,Marker, Biological,Marker, Clinical,Marker, Immunologic,Marker, Laboratory,Marker, Serum,Marker, Surrogate,Serum Marker,Surrogate End Point,Surrogate End Points,Surrogate Endpoint,Surrogate Endpoints,Surrogate Marker,Viral Marker,Biological Marker,End Point, Surrogate,End Points, Surrogate,Endpoint, Surrogate,Endpoints, Surrogate,Marker, Biologic,Marker, Immune,Marker, Viral,Markers, Biologic,Markers, Immune
D015870 Gene Expression The phenotypic manifestation of a gene or genes by the processes of GENETIC TRANSCRIPTION and GENETIC TRANSLATION. Expression, Gene,Expressions, Gene,Gene Expressions
D016159 Tumor Suppressor Protein p53 Nuclear phosphoprotein encoded by the p53 gene (GENES, P53) whose normal function is to control CELL PROLIFERATION and APOPTOSIS. A mutant or absent p53 protein has been found in LEUKEMIA; OSTEOSARCOMA; LUNG CANCER; and COLORECTAL CANCER. p53 Tumor Suppressor Protein,Cellular Tumor Antigen p53,Oncoprotein p53,TP53 Protein,TRP53 Protein,p53 Antigen,pp53 Phosphoprotein,Phosphoprotein, pp53

Related Publications

Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
April 2023, Metabolic brain disease,
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
January 2021, International journal of health sciences,
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
January 2014, Oncology reports,
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
January 2017, Journal of Cancer,
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
September 1997, Japanese journal of cancer research : Gann,
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
July 2022, Medical oncology (Northwood, London, England),
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
July 2020, Aging,
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
March 2009, Cell cycle (Georgetown, Tex.),
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
February 2002, The Journal of nutrition,
Tao Zhang, and Ling Hu, and Jia-Feng Tang, and Hang Xu, and Kuan Tian, and Meng-Na Wu, and Shi-Ying Huang, and Yu-Mei Du, and Peng Zhou, and Rui-Jin Lu, and Shuang He, and Jia-Mei Xu, and Jian-Jun Si, and Jing Li, and Di-Long Chen, and Jian-Hua Ran
May 2016, Molecular medicine reports,
Copied contents to your clipboard!